Comment from Robert Devine

Summary: The commenter, representing an industry entity, supports the proposed pilot program as a way to drive efficiency and industry-wide adoption of real-time clinical trials. They argue that the pilot builds on successful previous standards-based regulatory advancements and will significantly reduce sponsor burden while improving data quality and integrity through AI-enabled automation.